1.
2.
3.
Sheikh, M.; Roshandel, G.; McCormack, V.; Malekzadeh, R. Current Status and Future Prospects for Esophageal Cancer. Cancers
2023, 15, 765. [CrossRef] [PubMed]
Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour
and Welfare). Available online: https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a14 (accessed on 24 February 2023).
Watanabe, M.; Toh, Y.; Ishihara, R.; Kono, K.; Matsubara, H.; Miyazaki, T.; Morita, M.; Murakami, K.; Muro, K.; Numasaki, H.;
et al. Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus Off. J. Jpn. Esophageal Soc. 2023, 20, 1–28. [CrossRef]
[PubMed]
Cancers 2023, 15, 2987
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
21 of 23
Shimada, H.; Nabeya, Y.; Okazumi, S.-I.; Matsubara, H.; Shiratori, T.; Gunji, Y.; Kobayashi, S.; Hayashi, H.; Ochiai, T. Prediction of
survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003,
133, 486–494. [CrossRef] [PubMed]
Komohara, Y.; Fujiwara, Y.; Ohnishi, K.; Takeya, M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer
therapy. Adv. Drug Deliv. Rev. 2016, 99, 180–185. [CrossRef]
Shigeoka, M.; Urakawa, N.; Nakamura, T.; Nishio, M.; Watajima, T.; Kuroda, D.; Komori, T.; Kakeji, Y.; Semba, S.; Yokozaki, H.
Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma.
Cancer Sci. 2013, 104, 1112–1119. [CrossRef]
Urakawa, N.; Utsunomiya, S.; Nishio, M.; Shigeoka, M.; Takase, N.; Arai, N.; Kakeji, Y.; Koma, Y.-I.; Yokozaki, H. GDF15 derived
from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt
and Erk pathways. Lab. Investig. 2015, 95, 491–503. [CrossRef]
Hosono, M.; Koma, Y.-I.; Takase, N.; Urakawa, N.; Higashino, N.; Suemune, K.; Kodaira, H.; Nishio, M.; Shigeoka, M.; Kakeji,
Y.; et al. CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor
progression by promoting migration and invasion of cancer cells. Oncotarget 2017, 8, 106071–106088. [CrossRef]
Fujikawa, M.; Koma, Y.-I.; Hosono, M.; Urakawa, N.; Tanigawa, K.; Shimizu, M.; Kodama, T.; Sakamoto, H.; Nishio, M.; Shigeoka,
M.; et al. Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous
Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin
Pathway. Am. J. Pathol. 2021, 191, 686–703. [CrossRef]
Kodama, T.; Koma, Y.-I.; Arai, N.; Kido, A.; Urakawa, N.; Nishio, M.; Shigeoka, M.; Yokozaki, H. CCL3–CCR5 axis contributes to
progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways. Lab.
Investig. 2020, 100, 1140–1157. [CrossRef]
Tanigawa, K.; Tsukamoto, S.; Koma, Y.-I.; Kitamura, Y.; Urakami, S.; Shimizu, M.; Fujikawa, M.; Kodama, T.; Nishio, M.; Shigeoka,
M.; et al. S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration
and Invasion of Cancer Cells via Akt and p38 MAPK Pathways. Am. J. Pathol. 2022, 192, 536–552. [CrossRef]
Kodaira, H.; Koma, Y.; Hosono, M.; Higashino, N.; Suemune, K.; Nishio, M.; Shigeoka, M.; Yokozaki, H. ANXA10 induction by
interaction with tumor-associated macrophages promotes the growth of esophageal squamous cell carcinoma. Pathol. Int. 2019,
69, 135–147. [CrossRef] [PubMed]
Kitamura, Y.; Koma, Y.-I.; Tanigawa, K.; Tsukamoto, S.; Azumi, Y.; Miyako, S.; Urakami, S.; Kodama, T.; Nishio, M.; Shigeoka, M.;
et al. Roles of IL-7R Induced by Interactions between Cancer Cells and Macrophages in the Progression of Esophageal Squamous
Cell Carcinoma. Cancers 2023, 15, 394. [CrossRef] [PubMed]
Nishihira, T.; Hashimoto, Y.; Katayama, M.; Mori, S.; Kuroki, T. Molecular and cellular features of esophageal cancer cells. J.
Cancer Res. Clin. Oncol. 1993, 119, 441–449. [CrossRef] [PubMed]
Martens, M.; Ammar, A.; Riutta, A.; Waagmeester, A.; Slenter, D.N.; Hanspers, K.; Miller, R.A.; Digles, D.; Lopes, E.N.; Ehrhart, F.;
et al. WikiPathways: Connecting communities. Nucleic Acids Res. 2020, 49, D613–D621. [CrossRef] [PubMed]
Japanese Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: Part I. Esophagus 2016, 14, 1–36.
[CrossRef]
Japanese Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: Part II and III. Esophagus 2017, 14, 37–65.
[CrossRef]
Brierley, J.D.; Gospodarowicz, M.K.; Wittekind, C. TNM Classification of Malignant Tumours, 8th ed.; Wiley-Blackwell: Hoboken,
NJ, USA, 2016.
Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 2010, 141, 52–67.
[CrossRef]
Farina, A.R.; Mackay, A.R. Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers 2014, 6, 240–296. [CrossRef]
Mondal, S.; Adhikari, N.; Banerjee, S.; Amin, S.A.; Jha, T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A
minireview. Eur. J. Med. Chem. 2020, 194, 112260. [CrossRef]
Yu, X.-Y.; Lin, S.-C.; Zhang, M.-Q.; Guo, X.-T.; Ma, K.; Wang, L.-X.; Huang, W.-T.; Wang, Z.; Yu, X.; Wang, C.-G.; et al. Association
and prognostic significance of alpha-L-fucosidase-1 and matrix metalloproteinase 9 expression in esophageal squamous cell
carcinoma. World J. Gastrointest. Oncol. 2022, 14, 498–510. [CrossRef]
Ohashi, K.; Nemoto, T.; Nakamura, K.; Nemori, R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type
1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000, 88, 2201–2209. [CrossRef]
Mukherjee, S.; Roth, M.J.; Dawsey, S.M.; Yan, W.; Rodriguez-Canales, J.; Erickson, H.S.; Hu, N.; Goldstein, A.M.; Taylor, P.R.;
Richardson, A.M.; et al. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J. Transl. Med.
2010, 8, 91. [CrossRef] [PubMed]
Tanioka, Y.; Yoshida, T.; Yagawa, T.; Saiki, Y.; Takeo, S.; Harada, T.; Okazawa, T.; Yanai, H.; Okita, K. Matrix metalloproteinase-7
and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br. J. Cancer 2003,
89, 2116–2121. [CrossRef] [PubMed]
Liu, M.; Hu, Y.; Zhang, M.-F.; Luo, K.-J.; Xie, X.-Y.; Wen, J.; Fu, J.-H.; Yang, H. MMP1 promotes tumor growth and metastasis in
esophageal squamous cell carcinoma. Cancer Lett. 2016, 377, 97–104. [CrossRef] [PubMed]
Cancers 2023, 15, 2987
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
22 of 23
Fogg, K.C.; Olson, W.R.; Miller, J.N.; Khan, A.; Renner, C.; Hale, I.; Weisman, P.S.; Kreeger, P.K. Alternatively activated macrophagederived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway. Cancer Lett. 2019, 458, 92–101.
[CrossRef]
Carroll, M.J.; Kapur, A.; Felder, M.; Patankar, M.S.; Kreeger, P.K. M2 macrophages induce ovarian cancer cell proliferation via a
heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop. Oncotarget 2016, 7, 86608–86620.
[CrossRef]
Xu, Q.; Ma, H.; Chang, H.; Feng, Z.; Zhang, C.; Yang, X. The interaction of interleukin-8 and PTEN inactivation promotes the
malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway. Cell Death Dis. 2020, 11, 405. [CrossRef]
Yuan, X.; Li, Y.; Zhang, A.Z.; Jiang, C.H.; Li, F.P.; Xie, Y.F.; Li, J.F.; Liang, W.H.; Zhang, H.J.; Liu, C.X.; et al. Tumor-associated
macrophage polarization promotes the progression of esophageal carcinoma. Aging 2020, 13, 2049–2072. [CrossRef]
Kamoshida, G.; Matsuda, A.; Miura, R.; Takashima, Y.; Katsura, A.; Tsuji, T. Potentiation of tumor cell invasion by co-culture
with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin. Clin. Exp. Metastasis 2013, 30,
289–297. [CrossRef]
Komohara, Y.; Horlad, H.; Ohnishi, K.; Fujiwara, Y.; Bai, B.; Nakagawa, T.; Suzu, S.; Nakamura, H.; Kuratsu, J.-I.; Takeya, M.
Importance of direct macrophage—Tumor cell interaction on progression of human glioma. Cancer Sci. 2012, 103, 2165–2172.
[CrossRef]
Umakoshi, M.; Takahashi, S.; Itoh, G.; Kuriyama, S.; Sasaki, Y.; Yanagihara, K.; Yashiro, M.; Maeda, D.; Goto, A.; Tanaka,
M. Macrophage-mediated transfer of cancer-derived components to stromal cells contributes to establishment of a pro-tumor
microenvironment. Oncogene 2019, 38, 2162–2176. [CrossRef] [PubMed]
Wang, J.; Levenson, A.S.; Satcher, R.L. Identification of a unique set of genes altered during cell-cell contact in an in vitro model
of prostate cancer bone metastasis. Int. J. Mol. Med. 2006, 17, 849–856. [CrossRef] [PubMed]
Waltera, A.; Schulz, D.; Schaefer, N.; Stoeckl, S.; Pion, E.; Haerteis, S.; Reichert, T.E.; Ettl, T.; Bauer, R.J. Opposing MMP-9
Expression in Mesenchymal Stromal Cells and Head and Neck Tumor Cells after Direct 2D and 3D Co-Culture. Int. J. Mol. Sci.
2023, 24, 1293. [CrossRef] [PubMed]
Takaishi, K.; Komohara, Y.; Tashiro, H.; Ohtake, H.; Nakagawa, T.; Katabuchi, H.; Takeya, M. Involvement of M2-polarized
macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci.
2010, 101, 2128–2136. [CrossRef]
Ning, Y.; Cui, Y.; Li, X.; Cao, X.; Chen, A.; Xu, C.; Cao, J.; Luo, X. Co-culture of ovarian cancer stem-like cells with macrophages
induced SKOV3 cells stemness via IL-8/STAT3 signaling. Biomed. Pharmacother. 2018, 103, 262–271. [CrossRef]
Jia, Z.-H.; Jia, Y.; Guo, F.-J.; Chen, J.; Zhang, X.-W.; Cui, M.-H. Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production
in epithelial ovarian cancer. PLoS ONE 2017, 12, e0183622. [CrossRef]
Suzuki, T.; Kuwabara, Y.; Iwata, H.; Mitani, M.; Shinoda, N.; Sato, A.; Mitsui, A.; Sugiura, M.; Kato, J.; Fujii, Y. Role of matrix
metalloproteinase-9 in in vitro invasion of esophageal carcinoma cells. J. Surg. Oncol. 2002, 81, 80–86. [CrossRef]
Dufour, A.; Sampson, N.S.; Zucker, S.; Cao, J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J. Cell.
Physiol. 2008, 217, 643–651. [CrossRef]
Wang, X.-Q.; Sun, P.; Paller, A.S. Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association
with Integrin. J. Biol. Chem. 2003, 278, 25591–25599. [CrossRef]
Yu, Q.; Stamenkovic, I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated
tumor invasion. Genes Dev. 1999, 13, 35–48. [CrossRef]
Bannikov, G.A.; Karelina, T.V.; Collier, I.E.; Marmer, B.L.; Goldberg, G.I. Substrate Binding of Gelatinase B Induces Its Enzymatic
Activity in the Presence of Intact Propeptide. J. Biol. Chem. 2002, 277, 16022–16027. [CrossRef] [PubMed]
Tadbir, A.A.; Mardani, M.; Pourshahidi, S.; Nezarati, K.; Bahadori, P. Prognostic value of matrix metalloproteinase-9 expression in
oral squamous cell carcinoma and its association with angiogenesis. J. Clin. Exp. Dent. 2016, 8, e130–e135. [CrossRef]
Kabashima, A.; Maehara, Y.; Kakeji, Y.; Baba, H.; Koga, T.; Sugimachi, K. Clinicopathological features and overexpression of
matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin. Cancer Res. 2000, 6, 3581–3584.
Joseph, C.; Alsaleem, M.; Orah, N.; Narasimha, P.L.; Miligy, I.M.; Kurozumi, S.; Ellis, I.O.; Mongan, N.; Green, A.R.; Rakha, E.A.
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res. Treat. 2020, 182, 267–282.
[CrossRef] [PubMed]
Reis, S.T.; Leite, K.R.M.; Piovesan, L.F.; Pontes-Junior, J.; Viana, N.I.; Abe, D.K.; Crippa, A.; Moura, C.M.; Adonias, S.P.; Srougi, M.;
et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol. 2012, 12, 18.
[CrossRef]
Martins, J.M.A.; Rabelo-Santos, S.H.; Westin, M.C.D.A.; Zeferino, L.C. Tumoral and stromal expression of MMP-2, MMP-9,
MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: A competing risk analysis. BMC Cancer 2020, 20, 660.
[CrossRef]
Sillanpää, S.; Anttila, M.; Voutilainen, K.; Ropponen, K.; Turpeenniemi-Hujanen, T.; Puistola, U.; Tammi, R.; Tammi, M.; Sironen,
R.; Saarikoski, S.; et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol. Oncol.
2007, 104, 296–303. [CrossRef]
Cancers 2023, 15, 2987
50.
51.
52.
53.
23 of 23
Hu, J.M.; Liu, K.; Liu, J.H.; Jiang, X.L.; Wang, X.L.; Chen, Y.Z.; Li, S.G.; Zou, H.; Pang, L.J.; Liu, C.X.; et al. CD163 as a marker of
M2 macrophage, contribute to predicte aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma. Oncotarget
2017, 8, 21526–21538. [CrossRef]
Chakrabarti, S.; Patel, K.D. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J. Leukoc.
Biol. 2005, 78, 279–288. [CrossRef]
Van den Steen, P.E.; Proost, P.; Wuyts, A.; Van Damme, J.; Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8
tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.
Blood 2000, 96, 2673–2681. [CrossRef]
Blanchette-Farra, N.; Kita, D.; Konstorum, A.; Tesfay, L.; Lemler, D.; Hegde, P.; Claffey, K.P.; Torti, F.M.; Torti, S.V. Contribution
of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer. Oncogene 2018, 37,
4013–4032. [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
...
論文の公開元へ
